BROSSARD, QUEBEC--(Marketwired - Feb. 12, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today the opening of its Polish Subsidiary, Diagnos Poland spólka z ograniczoną odpowiedzialnością (Sp. z o.o.).

"Poland's central European location and substantial diabetic population, along with the strong support shown to Diagnos by local businesses and medical associations, make Poland an excellent place to establish a subsidiary. According to the International Diabetes Federation, there are over 2 million people in Poland suffering from diabetes and, like every other country in the world; this diabetic population is increasing at a steady rate. With our newest subsidiary, we are able to continue our business development in Poland and begin to close deals there. We have hired our first local employee ready to be deployed in a live screening event," said André Larente, DIAGNOS' President.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Andre Larente, President and CEO
1-877-678-8882 or (450) 678-8882, ext.: 224